Reff Mitchell E

TL;DR: In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement-dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellular cytotoxicity and the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma.

TL;DR: In this paper, therapeutic treatment protocols designed for the treatment of B cell lymphoma were presented, which are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti -CD20 antibody, and cooperative strategies comprising the using of chimeric antibody and radio-labeled antibody.

TL;DR: The gene encoding the rat glycosylation enzyme beta1-4-N-acetylglucosaminyltransferase III (GnTIII) was cloned and coexpressed in a recombinant production Chinese hamster ovary cell line expressing a chimeric mouse/human anti-CD20 IgG1 antibody.

TL;DR: Clenoliximab retains the key immunomodulatory attributes of keliximAB without the liability of strong Fcγ receptor binding, and in initial clinical trials, these properties have translated to a reduced incidence of CD4+ T cell depletion.

TL;DR: It is shown that cynomolgus macaques are phylogenetically distant enough to respond against conserved human antigens, and a human/monkey chimeric anti-CD4 antibody with an apparent affinity of 3.2 × 10−11 M and exhibits potent immunosuppressive properties in vitro.